This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Australian Government Invests In Detection And Management Of Blinding Eye Disease And Diabetes Through Intelligent High Resolution Retinal Camera Development By Vision CRC









SYDNEY, Feb. 18, 2013 /PRNewswire/ -- The most advanced technology for use in real-time detection and assessment of common blinding eye disease and general health disorders will soon be available to the world with stimulus funding provided for development by the Australian Government's CRC Program. The imaging technology of the breakthrough retinal camera is being developed by the Vision Cooperative Research Centre (Vision CRC) based in Sydney with international partners in Australia, US, China, India and Africa.



The world's first intelligent retinal camera will accurately and rapidly detect and eventually diagnose sight-threatening conditions such as diabetic retinopathy and glaucoma. The camera is being designed for ease of use in the most extreme environments so that it can be used by technical support staff and in the most remote and under-served locations, especially to close the gap in eye health in Australian Aboriginal communities.



CEO of Vision CRC and Brien Holden Vision Institute, Professor Brien Holden said today, "Medical devices of this nature are typically researched for use in affluent populations and aimed at high-end commercial returns. This Intelligent Retinal Camera (IRC) system will apply high resolution, multispectral imaging in an economic but high technology instrument that will be affordable and therefore accessible both in remote communities and in community health locations and professional offices throughout the world.



"Living in remote communities seriously disadvantages patients through lack of access to optometrists and ophthalmologists. The IRC will detect, measure and assess the potential for blinding disease thus preventing lengthy delay in getting treatment to those in need in marginalised communities. Aboriginal communities will be among the first to experience and benefit from this technology thanks to the funding from the Australian Government recently announced and the partnership with Aboriginal researchers and community health experts."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs